293 related articles for article (PubMed ID: 25843953)
21. A novel, soluble compound, C25, sensitizes to TRAIL-induced apoptosis through upregulation of DR5 expression.
James MA; Seibel WL; Kupert E; Hu XX; Potharla VY; Anderson MW
Anticancer Drugs; 2015 Jun; 26(5):518-30. PubMed ID: 25646742
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of preventive and therapeutic activity of novel non-steroidal anti-inflammatory drug, CG100649, in colon cancer: Increased expression of TNF-related apoptosis-inducing ligand receptors enhance the apoptotic response to combination treatment with TRAIL.
Woo JK; Kang JH; Jang YS; Ro S; Cho JM; Kim HM; Lee SJ; Oh SH
Oncol Rep; 2015 Apr; 33(4):1947-55. PubMed ID: 25672292
[TBL] [Abstract][Full Text] [Related]
23. Low-dose 5-fluorouracil sensitizes HepG2 cells to TRAIL through TRAIL receptor DR5 and survivin-dependent mechanisms.
Yang L; Wang Y; Zheng H; Zhang D; Wu X; Sun G; Yang T
J Chemother; 2017 Jun; 29(3):179-188. PubMed ID: 28067150
[TBL] [Abstract][Full Text] [Related]
24. Epigallocatechin-3-gallate Sensitizes Human 786-O Renal Cell Carcinoma Cells to TRAIL-Induced Apoptosis.
Wei R; Zhu G; Jia N; Yang W
Cell Biochem Biophys; 2015 May; 72(1):157-64. PubMed ID: 25539708
[TBL] [Abstract][Full Text] [Related]
25. 2-methoxy-5-amino-N-hydroxybenzamide sensitizes colon cancer cells to TRAIL-induced apoptosis by regulating death receptor 5 and survivin expression.
Stolfi C; Caruso R; Franzè E; Rizzo A; Rotondi A; Monteleone I; Fantini MC; Pallone F; Monteleone G
Mol Cancer Ther; 2011 Oct; 10(10):1969-81. PubMed ID: 21817114
[TBL] [Abstract][Full Text] [Related]
26. Repeated treatment with subtoxic doses of TRAIL induces resistance to apoptosis through its death receptors in MDA-MB-231 breast cancer cells.
Yoshida T; Zhang Y; Rivera Rosado LA; Zhang B
Mol Cancer Res; 2009 Nov; 7(11):1835-44. PubMed ID: 19843632
[TBL] [Abstract][Full Text] [Related]
27. The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells.
Liu X; Yue P; Chen S; Hu L; Lonial S; Khuri FR; Sun SY
Cancer Res; 2007 May; 67(10):4981-8. PubMed ID: 17510429
[TBL] [Abstract][Full Text] [Related]
28. Glucocorticoid receptor antagonist sensitizes TRAIL-induced apoptosis in renal carcinoma cells through up-regulation of DR5 and down-regulation of c-FLIP(L) and Bcl-2.
Min KJ; Jang JH; Lee JT; Choi KS; Kwon TK
J Mol Med (Berl); 2012 Mar; 90(3):309-19. PubMed ID: 22008998
[TBL] [Abstract][Full Text] [Related]
29. Dicoumarol sensitizes renal cell carcinoma Caki cells to TRAIL-induced apoptosis through down-regulation of Bcl-2, Mcl-1 and c-FLIP in a NQO1-independent manner.
Park EJ; Min KJ; Choi KS; Kwon TK
Exp Cell Res; 2014 Apr; 323(1):144-154. PubMed ID: 24462458
[TBL] [Abstract][Full Text] [Related]
30. Nutlin-3, a small-molecule MDM2 inhibitor, sensitizes Caki cells to TRAIL-induced apoptosis through p53-mediated PUMA upregulation and ROS-mediated DR5 upregulation.
Park EJ; Choi KS; Yoo YH; Kwon TK
Anticancer Drugs; 2013 Mar; 24(3):260-9. PubMed ID: 23187459
[TBL] [Abstract][Full Text] [Related]
31. Acrolein sensitizes human renal cancer Caki cells to TRAIL-induced apoptosis via ROS-mediated up-regulation of death receptor-5 (DR5) and down-regulation of Bcl-2.
Yang ES; Woo SM; Choi KS; Kwon TK
Exp Cell Res; 2011 Nov; 317(18):2592-601. PubMed ID: 21854768
[TBL] [Abstract][Full Text] [Related]
32. Lexatumumab (TRAIL-receptor 2 mAb) induces expression of DR5 and promotes apoptosis in primary and metastatic renal cell carcinoma in a mouse orthotopic model.
Zhang L; Zhang X; Barrisford GW; Olumi AF
Cancer Lett; 2007 Jun; 251(1):146-57. PubMed ID: 17184908
[TBL] [Abstract][Full Text] [Related]
33. ABC294640, a sphingosine kinase 2 inhibitor, enhances the antitumor effects of TRAIL in non-small cell lung cancer.
Yang J; Yang C; Zhang S; Mei Z; Shi M; Sun S; Shi L; Wang Z; Wang Y; Li Z; Xie C
Cancer Biol Ther; 2015; 16(8):1194-204. PubMed ID: 26054751
[TBL] [Abstract][Full Text] [Related]
34. Novel histone deacetylase inhibitors derived from Magnolia officinalis significantly enhance TRAIL-induced apoptosis in non-small cell lung cancer.
Liu Y; Tong Y; Yang X; Li F; Zheng L; Liu W; Wu J; Ou R; Zhang G; Hu M; Liu Z; Lu L
Pharmacol Res; 2016 Sep; 111():113-125. PubMed ID: 27268146
[TBL] [Abstract][Full Text] [Related]
35. Down-regulation of Cbl-b by bufalin results in up-regulation of DR4/DR5 and sensitization of TRAIL-induced apoptosis in breast cancer cells.
Yan S; Qu X; Xu C; Zhu Z; Zhang L; Xu L; Song N; Teng Y; Liu Y
J Cancer Res Clin Oncol; 2012 Aug; 138(8):1279-89. PubMed ID: 22447040
[TBL] [Abstract][Full Text] [Related]
36. Linarin sensitizes tumor necrosis factor-related apoptosis (TRAIL)-induced ligand-triggered apoptosis in human glioma cells and in xenograft nude mice.
Xu ZF; Sun XK; Lan Y; Han C; Zhang YD; Chen G
Biomed Pharmacother; 2017 Nov; 95():1607-1618. PubMed ID: 28950661
[TBL] [Abstract][Full Text] [Related]
37. The farnesyltransferase inhibitor R115777 up-regulates the expression of death receptor 5 and enhances TRAIL-induced apoptosis in human lung cancer cells.
Qiu Y; Liu X; Zou W; Yue P; Lonial S; Khuri FR; Sun SY
Cancer Res; 2007 May; 67(10):4973-80. PubMed ID: 17510428
[TBL] [Abstract][Full Text] [Related]
38. Compound C sensitizes Caki renal cancer cells to TRAIL-induced apoptosis through reactive oxygen species-mediated down-regulation of c-FLIPL and Mcl-1.
Jang JH; Lee TJ; Yang ES; Min do S; Kim YH; Kim SH; Choi YH; Park JW; Choi KS; Kwon TK
Exp Cell Res; 2010 Aug; 316(13):2194-203. PubMed ID: 20451517
[TBL] [Abstract][Full Text] [Related]
39. Chloroquine enhances TRAIL-mediated apoptosis through up-regulation of DR5 by stabilization of mRNA and protein in cancer cells.
Park EJ; Min KJ; Choi KS; Kubatka P; Kruzliak P; Kim DE; Kwon TK
Sci Rep; 2016 Mar; 6():22921. PubMed ID: 26964637
[TBL] [Abstract][Full Text] [Related]
40. Antimycin A sensitizes cells to TRAIL-induced apoptosis through upregulation of DR5 and downregulation of c-FLIP and Bcl-2.
Lee SJ; Kim EA; Song KS; Kim MJ; Lee DH; Kwon TK; Lee TJ
Int J Oncol; 2012 Oct; 41(4):1425-30. PubMed ID: 22842544
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
